TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20569228

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa (LD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) + Levodopa (LD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19376304

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin (INR 2-3)
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran (both doses)
Number of subjects: 18113
Study: 17079994

Group type: EXPERIMENTAL
Intervention: Antimalarial treatment
Number of subjects: 327
Study: 15648729

Group type: EXPERIMENTAL
Intervention: Spatial tapping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Articulatory suppression
Number of subjects: 0
Study: 11336370

Group type: EXPERIMENTAL
Intervention: Intra-articular ropivacaine injection (20 ml of ropivacaine 0.5%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline injection (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-articular ropivacaine injection
Number of subjects: 100
Study: 9138046

Group type: EXPERIMENTAL
Intervention: 12-week group cognitive-behavioral therapy (CBT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Extended cognitive-behavioral therapy (CBT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 46
Study: 7618614

Group type: EXPERIMENTAL
Intervention: Plasma atrial natriuretic factor (ANF)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Plasma endothelin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Plasma ANF
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Killip classification
Number of subjects: 145
Study: 2751476

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg twice daily)
Number of subjects: 12
Study: 950094

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic cholangiography with the Chiba needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography (after initial failure of percutaneous)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic cholangiography (after initial failure of endoscopic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic cholangiography
Number of subjects: 60

Group type: COMPARATOR
Intervention: Complications after endoscopic retrograde cholangiography
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Complications after percutaneous transhepatic cholangiography
Number of subjects: 60
Study: 30771727

Group type: EXPERIMENTAL
Intervention: sparse pre‐trained random vector functional link (SP‐RVFL) network
Number of subjects: 0

Group type: COMPARATOR
Intervention: random vector functional link (RVFL)
Number of subjects: 0
Study: 25987796

Group type: EXPERIMENTAL
Intervention: Oral administration of Alequel™, an autologous protein‐containing colon extract, 3 doses per week for 15 weeks (total of 45 doses)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oral administration of Alequel™, an autologous protein‐containing colon extract
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 23276620

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21466598

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO) diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dairy fat (DF) diet
Number of subjects: 20
Study: 18287392

Group type: EXPERIMENTAL
Intervention: Orthosolo universal bond enhancer
Number of subjects: 33

Group type: COMPARATOR
Intervention: Transbond XT primer
Number of subjects: 33
Study: 16449370

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 20
Study: 12953157

Group type: COMPARATOR
Intervention: Ocular Hypertension (OHT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Primary Open Angle Glaucoma (POAG)
Number of subjects: 79
Study: 10875716

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron and 1.25 mg droperidol combination
Number of subjects: 160

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 160
Study: 8979387

Group type: EXPERIMENTAL
Intervention: Individual success feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual failure feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual failure feedback (for low-self-esteem group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual success feedback (in in-group failure/out-group success condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual failure feedback (in in-group failure/out-group success condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yoked-control observer individuals
Number of subjects: 0
Study: 1355599

Group type: EXPERIMENTAL
Intervention: Pipecuronium 80 micrograms/kg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pancuronium 100 micrograms/kg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Atracurium 500 micrograms/kg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Neostigmine (administered after vecuronium or atracurium)
Number of subjects: 62
Study: 6339331

Group type: EXPERIMENTAL
Intervention: Doxycycline (single-dose prophylactic antibiotic)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no doxycycline)
Number of subjects: 64
Study: 30597114

Group type: EXPERIMENTAL
Intervention: Self-medication with antimicrobials
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Self-medication with antihypertensives or antihyperglycemics
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Self-treatment with antimicrobials
Number of subjects: 718
Study: 28851037

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ARV)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: ARV and LNS
Number of subjects: 535

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Overall treatment groups
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Maternal haemoglobin
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Milk minerals
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Moderately anaemic women
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Mildly anaemic women
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Infant TfR
Number of subjects: 535
Study: 27662556

Group type: EXPERIMENTAL
Intervention: Continuing cotrimoxazole
Number of subjects: 758

Group type: COMPARATOR
Intervention: Stopping cotrimoxazole
Number of subjects: 758
Study: 24077374

Group type: EXPERIMENTAL
Intervention: Constant Torque (CT) stretching
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Constant Angle (CA) stretching
Number of subjects: 23
Study: 22406059

Group type: EXPERIMENTAL
Intervention: Excimer laser atherectomy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control population from the SAFER trial
Number of subjects: 98
Study: 19013761

Group type: EXPERIMENTAL
Intervention: Drug therapies in RCTs
Number of subjects: 6
Study: 17166731

Group type: EXPERIMENTAL
Intervention: Transcervical extended mediastinal lymphadenectomy (TEMLA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard mediastinoscopy
Number of subjects: 41
Study: 16027405

Group type: EXPERIMENTAL
Intervention: Quercetin + Rosiglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Rosiglitazone
Number of subjects: 0
Study: 12213870

Group type: EXPERIMENTAL
Intervention: Surgery (n = 11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) 60 mg/month (n = 11)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients with uncontrolled disease (n = 13)
Number of subjects: 35
Study: 9823652

Group type: EXPERIMENTAL
Intervention: Cavaterm balloon coagulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: roller-ball endometrium coagulation
Number of subjects: 20
Study: 10233220

Group type: EXPERIMENTAL
Intervention: Urea-containing moisturizer applied twice daily for 20 days
Number of subjects: 15
Study: 2379229

Group type: EXPERIMENTAL
Intervention: Clindamycin 150 mg orally four times daily for seven days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ampicillin 250 mg orally four times daily for seven days
Number of subjects: 106
Study: 78297

Group type: EXPERIMENTAL
Intervention: Salbutamol inhalers used 30 min before inhalation of 100 microgram of beclomethasone dipropionate (B.D.P.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 18
Study: 31368583

Group type: EXPERIMENTAL
Intervention: Do More, Feel Better
Number of subjects: 18

Group type: COMPARATOR
Intervention: Referral to mental health services
Number of subjects: 18
Study: 25399552

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m² every 3 weeks)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 418

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 418
Study: 23807124

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Traditional postoperative care (TPC)
Number of subjects: 295
Study: 22152871

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) for 1 to 2 months, 20 minutes, 3 times a week
Number of subjects: 39
Study: 19218908

Group type: EXPERIMENTAL
Intervention: Innovative diagnostic and therapeutic developments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical resection of early melanoma
Number of subjects: 0
Study: 16954710

Group type: EXPERIMENTAL
Intervention: Topical 2% lidocaine gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Artificial tear gel
Number of subjects: 45
Study: 14722682

Group type: EXPERIMENTAL
Intervention: Thallium-201 SPET
Number of subjects: 32

Group type: COMPARATOR
Intervention: CT/MRI
Number of subjects: 32
Study: 11413357

Group type: COMPARATOR
Intervention: Hypoxia + placebo (HP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxia + salbutamol (NS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hypoxia + salbutamol (HS)
Number of subjects: 8
Study: 9404429

Group type: EXPERIMENTAL
Intervention: Target group DBP <= 90 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target group DBP <= 85 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target group DBP <= 80 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bitherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tritherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence of side effects over time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional influence on side effects
Number of subjects: 0
Study: 8236548

Group type: EXPERIMENTAL
Intervention: Pravastatin (Pravachol)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 3524643

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 199
Study: 31928023

Group type: EXPERIMENTAL
Intervention: Brief psychosocial intervention
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic psychotherapy
Number of subjects: 35
Study: 29442086

Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen orally 1 h before the endodontic procedure (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-level laser irradiation at 50 Hz for 3 min after the endodontic procedure (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen and low-level laser therapy (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No preoperative ibuprofen nor low-level laser irradiation (Group D)
Number of subjects: 120
Study: 26968380

Group type: COMPARATOR
Intervention: Moderate hyperoxia (PaO2 target of 200-220 mmHg during cardiopulmonary bypass and 130-150 mmHg during ICU admission)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Near-physiological oxygen strategy (PaO2 target of 130-150 mmHg during cardiopulmonary bypass and 80-100 mmHg during ICU admission)
Number of subjects: 50
Study: 24012063

Group type: EXPERIMENTAL
Intervention: Combined oral and enema mesalazine (4 g/day oral + 1 g enema)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined oral and enema mesalazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral mesalazine (4 g/day)
Number of subjects: 0
Study: 22311905

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Enteric-coated aspirin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Immediate-release aspirin
Number of subjects: 135
Study: 20696865

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 451
Study: 18715213

Group type: EXPERIMENTAL
Intervention: Insulin guidance software (ACCU‐CHEK Advisor)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 15761191

Group type: EXPERIMENTAL
Intervention: Torcetrapib (120 mg QD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Torcetrapib (120 mg BID)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 19
Study: 12454555

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75 to 225 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (37.5 mg, 75 mg, or 150 mg, fixed-dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10622338

Group type: EXPERIMENTAL
Intervention: Fast rTMS (10 Hz)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Slow rTMS (0.3 Hz)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 8717568

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine delivered by wound catheter
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 70
Study: 1673944

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 10 mg BID
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined therapy (medroxyprogesterone acetate and conjugated estrogens)
Number of subjects: 36
Study: 6108592

Group type: EXPERIMENTAL
Intervention: Nabilone (4 or 5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nabilone (1 or 2 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nabilone (comparatively lower doses)
Number of subjects: 8
Study: 31940784

Group type: EXPERIMENTAL
Intervention: DYNAMAP system for noise monitoring
Number of subjects: 21

Group type: COMPARATOR
Intervention: Field measurements of noise levels
Number of subjects: 21
Study: 31136050

Group type: EXPERIMENTAL
Intervention: Digitally hydroformed reconstruction plate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manually prebent reconstruction plate
Number of subjects: 12
Study: 28911510

Group type: EXPERIMENTAL
Intervention: Gasping during CPR
Number of subjects: 1827

Group type: COMPARATOR
Intervention: No gasping during CPR (Control)
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Gasping combined with shockable initial recorded rhythm
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Shockable initial recorded rhythm
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Shorter CPR duration
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Lower epinephrine dosage
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Pulmonary edema
Number of subjects: 1827
Study: 26285325

Group type: EXPERIMENTAL
Intervention: Respiratory and relaxation training
Number of subjects: 62
Study: 23959833

Group type: EXPERIMENTAL
Intervention: MTHFR 677 TT genotype
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MTHFR T allele
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MTRR 66 GG
Number of subjects: 600
Study: 20852441

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 28
Study: 19584831

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2b alone (100 microg per week)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2b and lamivudine (100 mg/day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: HBeAg loss within 32 weeks
Number of subjects: 172

Group type: COMPARATOR
Intervention: HBeAg loss after week 32
Number of subjects: 172
Study: 17426158

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (25 mg/kg of the sulfadoxine component)
Number of subjects: 111
Study: 15198277

Group type: EXPERIMENTAL
Intervention: zaleplon 10 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: zopiclone 7.5 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: temazepam 15 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: time‐released melatonin 6 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 11351356

Group type: EXPERIMENTAL
Intervention: Pycnogenol (50 mg x 3/day for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9437195

Group type: COMPARATOR
Intervention: Alpha-tocopherol (50 mg daily)
Number of subjects: 26289

Group type: COMPARATOR
Intervention: Beta-carotene (20 mg daily)
Number of subjects: 26289

Group type: COMPARATOR
Intervention: Alpha-tocopherol and beta-carotene (50 mg and 20 mg daily respectively)
Number of subjects: 26289

Group type: COMPARATOR
Intervention: No alpha-tocopherol
Number of subjects: 26289

Group type: COMPARATOR
Intervention: No beta-carotene
Number of subjects: 26289
Study: 7893581

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 20
Study: 3287167

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg per day, five days per week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 100
Study: 30626196

Group type: EXPERIMENTAL
Intervention: BattleViro (ART-related iPhone game)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-HIV-related game (Control)
Number of subjects: 61
Study: 27330807

Group type: EXPERIMENTAL
Intervention: CVac maintenance treatment (10 doses over 56 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard of care (SOC) observation
Number of subjects: 56
Study: 25792354

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance through an impedance threshold device (ITD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham device (no resistance)
Number of subjects: 26
Study: 23096417

Group type: EXPERIMENTAL
Intervention: Remote programming using a remote-presence robot (RP-7) with expert telementoring of nonexpert nurses.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional programming sessions.
Number of subjects: 20
Study: 20943270

Group type: EXPERIMENTAL
Intervention: Emotional abuse in women
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Sexual abuse in women
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Physical punishment in women
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Emotional neglect in women
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Emotional neglect in men
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Sexual abuse in men
Number of subjects: 2782
Study: 18300236

Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg orally twice daily and bevacizumab 5 mg/kg to 10 mg/kg intravenously every 2 weeks for 28-day cycles
Number of subjects: 15

Group type: COMPARATOR
Intervention: CA125 criteria
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined imaging and CA125 criteria
Number of subjects: 15
Study: 16614544

Group type: EXPERIMENTAL
Intervention: Reboxetine (1 week placebo lead-in)
Number of subjects: 0
Study: 12796772

Group type: EXPERIMENTAL
Intervention: Low dose (4 x 10(9) particle units)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High dose (4 x 10(10) particle units)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 11195956

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) combined with Medroxyprogesterone acetate (MPA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: E2V-CPA (estradiol valerate combined with cyproterone acetate)
Number of subjects: 81
Study: 8866624

Group type: EXPERIMENTAL
Intervention: Mepyramine (0.5 mg.kg‐1) pretreatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 7
Study: 1346499

Group type: EXPERIMENTAL
Intervention: Prednisone and plasma exchange (group A)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Prednisone alone (group B)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide or dapsone therapy (as second-line treatment)
Number of subjects: 78